# FDA 483 - Cantor BioConnect, Inc. - March 24, 2026

Source: https://www.keypedia.com/records/483/cantor-bioconnect-inc/e5bef515-4b21-4dc3-9eba-004df0a7a897

> FDA 483 for Cantor BioConnect, Inc. on March 24, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Cantor BioConnect, Inc.
- Inspection Date: 2026-03-24
- Product Type: biologics
- Office Name: Division of Pharmaceutical Quality Operations IV
- Summary: Cantor BioConnect, Inc., a blood component storage and distribution facility in Santee, CA, received a Form 483 with two observations. The inspection revealed deficiencies in the firm's complaint handling system for distributed biological products and a failure to conduct preventive maintenance on -20°C freezers according to manufacturer specifications. These issues indicate a need for improved quality system procedures and equipment management.

## Related Officers

- [Creighton T. Tuzon](https://www.keypedia.com/people/creighton-t-tuzon/be0d09c0-59f4-48c3-9e3d-a1ceb2587e3e)
- [James A. Banks](https://www.keypedia.com/people/james-a-banks/6838e911-c630-4a7c-8198-f3936ef6c5f8)

Company: https://www.keypedia.com/companies/cantor-bioconnect-inc/981435e7-15fc-4730-bb5e-ceb13c11f367

Office: https://www.keypedia.com/offices/division-of-pharmaceutical-quality-operations-iv/a2d2ff91-dc0f-433e-b91f-ca90ff8998b6